SCHEMBL7838457

SCHEMBL7838457

[CH2]c1ccc2c(O)cccc2c1

nearest known ligand 0.59

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PLAU P00749 1/20 0.59
HSD17B1 P14061 11/20 0.55
HSD17B2 P37059 11/20 0.55
ESR1 P03372 3/20 0.55
ESR2 Q92731 3/20 0.55
CYP1A2 P05177 1/20 0.54
GRIN2D O15399 1/20 0.44
GRIN2A Q12879 1/20 0.44
GRIN2B Q13224 1/20 0.44
GRIN2C Q14957 1/20 0.44
KDM4E B2RXH2 1/20 0.44
MAPKAPK2 P49137 1/20 0.44
CTDSP1 Q9GZU7 1/20 0.44
NQO2 P16083 1/20 0.43
IDO1 P14902 1/20 0.41
TDO2 P48775 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4610309 0.83 CTDSP1 (0.59) PLAUHSD17B1HSD17B2ESR1ESR2
SCHEMBL29364213 0.77 HSD17B1 (0.70) PLAUHSD17B1HSD17B2ESR1ESR2
SCHEMBL29738652 0.77 HSD17B1 (0.70) PLAUHSD17B1HSD17B2ESR1ESR2
SCHEMBL444105 0.77 HSD17B1 (0.84) PLAUHSD17B1HSD17B2ESR1ESR2
SCHEMBL15451 0.77 HSD17B1 (0.70) PLAUHSD17B1HSD17B2ESR1ESR2
SCHEMBL29857010 0.76 CYP1A2 (0.62) PLAUHSD17B1HSD17B2ESR1ESR2
SCHEMBL2115683 0.76 CYP1A2 (0.62) PLAUHSD17B1HSD17B2ESR1ESR2
SCHEMBL158141 0.76 NQO2 (0.61) PLAUHSD17B1HSD17B2ESR1ESR2
Hydrogen Sulfide SCHEMBL28751866 0.76 HSD17B1 (0.68) PLAUHSD17B1HSD17B2ESR1ESR2
Hydrochloric Acid SCHEMBL29701293 0.76 HSD17B1 (0.68) PLAUHSD17B1HSD17B2ESR1ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0676398-B1 Heterocyclic compounds having anti-diabetic activity, their preparation and their use SANKYO CO (JP) 2001-10-24 EP disclosed
CN-1066729-C Benzimidazole derivatives, their preparation and their therapeutic use SANKYO CO (JP) 2001-06-06 CN disclosed
US-6117893-A Heterocyclic compounds having anti-diabetic activity and their use SANKYO COMPANY, LIMITED (JP) 2000-09-12 US disclosed
EP-1022274-A1 Oxazolidinedione and Thiazolidinedione derivatves, their preparation and their use Sankyo Company Limited (JP) 2000-07-26 EP disclosed
US-5977365-A HYPOGLYCEMIC AGENTS SANKYO COMPANY, LIMITED (JP) 1999-11-02 US disclosed
US-5962470-A Heterocyclic compounds having anti-diabetic activity and their use SANKYO COMPANY, LIMITED (JP) 1999-10-05 US disclosed
US-5886014-A TREATMENT AND/OR PROPHYLAXIS OF A VARIETY OF DISORDERS, INCLUDING HYPERLIPEMIA, HYPERGLYCEMIA, OBESITY, IMPAIRED GLUCOSE TOLERANCE (IGT), INSULIN RESISTANCE AND DIABETIC COMPLICATIONS SANKYO COMPANY, LIMITED (JP) 1999-03-23 US disclosed
US-5834501-A TREATING DIABETES OR HYPERLIPEMIA SANKYO COMPANY, LIMITED (JP) 1998-11-10 US disclosed
US-5739345-A HYPOGLYCEMIC AND ANTIDIABETIC AGENTS SANKYO COMPANY, LIMITED (JP) 1998-04-14 US disclosed
CN-1157288-A Benzimidazole derivatives, their preparation and their therapeutic use SANKYO CO (JP) 1997-08-20 CN disclosed
US-5624935-A ANTIDIABETIC AGENTS, HYPOGLYCEMIC AGENTS OR ANTILIPEMIC AGENTS SANKYO COMPANY, LIMITED 1997-04-29 US disclosed
EP-0745600-A1 Benzimidazole derivatives, their preparation and their therapeutic use SANKYO COMPANY LIMITED (JP) 1996-12-04 EP disclosed
EP-0676398-A2 Heterocyclic compounds having anti-diabetic activity, their preparation and their use SANKYO COMPANY LIMITED (JP) 1995-10-11 EP disclosed